304 related articles for article (PubMed ID: 15561867)
1. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells.
Govorkova EA; Fang HB; Tan M; Webster RG
Antimicrob Agents Chemother; 2004 Dec; 48(12):4855-63. PubMed ID: 15561867
[TBL] [Abstract][Full Text] [Related]
2. Utilization of the embryonated egg for in vivo evaluation of the anti-influenza virus activity of neuraminidase inhibitors.
Sauerbrei A; Haertl A; Brandstaedt A; Schmidtke M; Wutzler P
Med Microbiol Immunol; 2006 Jun; 195(2):65-71. PubMed ID: 16059699
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.
McSharry JJ; McDonough AC; Olson BA; Drusano GL
Clin Diagn Lab Immunol; 2004 Jan; 11(1):21-8. PubMed ID: 14715540
[TBL] [Abstract][Full Text] [Related]
4. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.
Molla A; Kati W; Carrick R; Steffy K; Shi Y; Montgomery D; Gusick N; Stoll VS; Stewart KD; Ng TI; Maring C; Kempf DJ; Kohlbrenner W
J Virol; 2002 Jun; 76(11):5380-6. PubMed ID: 11991966
[TBL] [Abstract][Full Text] [Related]
5. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
Govorkova EA; Leneva IA; Goloubeva OG; Bush K; Webster RG
Antimicrob Agents Chemother; 2001 Oct; 45(10):2723-32. PubMed ID: 11557461
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
Gubareva LV; Webster RG; Hayden FG
Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
[TBL] [Abstract][Full Text] [Related]
7. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus.
Abed Y; Goyette N; Boivin G
Antivir Ther; 2004 Aug; 9(4):577-81. PubMed ID: 15456089
[TBL] [Abstract][Full Text] [Related]
8. Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host.
Thompson CI; Barclay WS; Zambon MC
J Antimicrob Chemother; 2004 May; 53(5):759-65. PubMed ID: 15028666
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
Ferraris O; Kessler N; Lina B
Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
[TBL] [Abstract][Full Text] [Related]
10. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia.
Hurt AC; Barr IG; Durrant CJ; Shaw RP; Sjogren HM; Hampson AW
Commun Dis Intell Q Rep; 2003; 27(4):542-7. PubMed ID: 15508516
[TBL] [Abstract][Full Text] [Related]
11. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium.
Hayden FG; Rollins BS; Madren LK
Antiviral Res; 1994 Oct; 25(2):123-31. PubMed ID: 7847874
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
Hurt AC; Barr IG; Hartel G; Hampson AW
Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
Bantia S; Parker CD; Ananth SL; Horn LL; Andries K; Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin T; Hutchison TL; Montgomery JA; Kellog DL; Babu YS
Antimicrob Agents Chemother; 2001 Apr; 45(4):1162-7. PubMed ID: 11257030
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid.
Gubareva LV; Penn CR; Webster RG
Virology; 1995 Oct; 212(2):323-30. PubMed ID: 7571401
[TBL] [Abstract][Full Text] [Related]
15. In vitro efficacies of oseltamivir carboxylate and zanamivir against equine influenza A viruses.
Yamanaka T; Tsujimura K; Kondo T; Matsumura T
J Vet Med Sci; 2006 Apr; 68(4):405-8. PubMed ID: 16679737
[TBL] [Abstract][Full Text] [Related]
16. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
Mungall BA; Xu X; Klimov A
Virus Res; 2004 Jul; 103(1-2):195-7. PubMed ID: 15163509
[TBL] [Abstract][Full Text] [Related]
17. Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir.
Wang MZ; Tai CY; Mendel DB
Antimicrob Agents Chemother; 2002 Dec; 46(12):3809-16. PubMed ID: 12435681
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of synergistic inhibitory effects of neuraminidase inhibitors and methylglyoxal against influenza virus infection.
Charyasriwong S; Watanabe K; Rahmasari R; Matsunaga A; Haruyama T; Kobayashi N
Arch Med Res; 2015 Jan; 46(1):8-16. PubMed ID: 25523147
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor.
Sidwell RW; Huffman JH; Barnard DL; Bailey KW; Wong MH; Morrison A; Syndergaard T; Kim CU
Antiviral Res; 1998 Feb; 37(2):107-20. PubMed ID: 9588843
[TBL] [Abstract][Full Text] [Related]
20. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro.
Woods JM; Bethell RC; Coates JA; Healy N; Hiscox SA; Pearson BA; Ryan DM; Ticehurst J; Tilling J; Walcott SM
Antimicrob Agents Chemother; 1993 Jul; 37(7):1473-9. PubMed ID: 8363379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
